Close Menu

NEW YORK – A group of researchers led by the New York University School of Medicine and the US Army Medical Research and Development Command has developed a blood-based assay that relies on a variety of molecular and physiological biomarkers to detect cases of post-traumatic stress disorder (PTSD).

While the test is still in its very early stages, the researchers intend to eventually commercialize the 28-biomarker panel for military veterans and civilians who show early symptoms of post-traumatic stress disorder. 

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.